Skip to main content

Table 2 Clinical Management and Outcomes in Pseudomonas aeruginosa bacteraemia

From: The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study

  All patients
(n = 128)
+IDC
(n = 91)
-IDC
(n = 37)
P Value
30-day mortality: n (%) 31 (24.2) 10 (11.0) 21 (56.8) < 0.001
Intensive care unit admission: n (%) 63 (49.2) 40 (44.0) 23 (62.2) 0.163
Acquisition of PAB: n (%)     0.223
 Community acquired 50 (39.1) 32 (35.2) 18 (48.6)
 Hospital acquired 78 (60.9) 59 (64.8) 19 (51.4)
Length of stay in hospital (days; mean, standard deviation) 15.5, 7.8 16.7, 8.5 12.9, 5.7 0.248
Inappropriate or no antibiotica: n (%) 40 (31.3) 24 (26.4) 16 (43.2) 0.060
Inappropriate duration of antibiotic: n (%) 29 (22.7) 4 (4.4) 25 (67.6) < 0.001
De-escalation to oral antibiotic in a timely manner: n (%) 95 (74.2) 80 (87.9%) 15 (40.5%) < 0.001
Source of PAB: n (%)     0.786
 Unidentified 41 (32.0) 28 (30.8) 13 (35.1)
 Identified 87 (68.0) 63 (69.2) 24 (64.9)
  Intravascular catheter 32 (25.0) 26 (28.6) 6 (16.2)
  Pulmonary infection 20 (15.6) 11 (12.1) 9 (24.3)
  Urinary tract infection 18 (14.1) 14 (15.4) 4 (10.8)
  Skin and soft tissue infection 13 (10.2) 10 (11.0) 3 (8.1)
  Other 4 (3.1) 2 (2.2) 2 (5.4)
Removal of infected catheter: n (%) 30 (23.4) 25 (27.5) 5 (13.5) 0.049
Surgical intervention for source control: n (%) 21 (16.4) 19 (20.9) 2 (5.4) 0.023
  1. Abbreviations: PA Pseudomonas aeruginosa, PAB Pseudomonas aeruginosa bacteraemia, +IDC received infectious diseases specialist consultation, −IDC did not receive infectious diseases specialist consultation. aOnly one person did not receive antibiotic as per patient’s advanced care plan in the event of septic shock